FDA
-
-
-
-
-
-
-
BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno
-
-
-
-
-
-
-
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up
-
-
-
-
-
-
-
BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP® Cell Therapy in Ischemic Heart Failure
-
-
-
-
-
-
-
BioCardia's (BCDA) Phase 3 CardiAMP-HF Trial Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years
-
-
-
-
-
-
-
BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions
-
-
-
-
-
-
-
BioCardia (BCDA) Regains Full Compliance with Nasdaq Listing Requirements
-
-
-
-
-
-
-
BioCardia (BCDA) Submits for FDA Approval of Morph DNA
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

